In March 2025, vTv Therapeutics announced that the clinical hold placed by the FDA in July 2024 on the cadisegliatin clinical program was lifted on March 14, 2025, following the Company's ...

Cheap, broad exposure to large-value stocks. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market ...

On July 26, 2024, vTv Therapeutics announced a clinical hold on the CATT1 Phase 3 trial based on the discovery of a chromatographic signal in a human absorption, distribution, metabolism ...

VOV.VN - Báo điện tử VOV, tin tức thời sự về chính trị, kinh tế, đời sống, xã hội, pháp luật, thể thao, văn hóa, giải trí, ...

VTV is a passively managed fund that follows a full-replication strategy. The ETF was established on January 26, 2004. Since April 24, 2024, the fund’s expense ratio has been 0.04%. Its 30-day ...

vTv Therapeutics expects to resume the trial ... insulin alone after reinitiating the CATT1 Phase 3 trial.” In July 2024, the FDA placed a clinical hold on the cadisegliatin clinical program.

HIGH POINT, N.C. - vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company with a market capitalization of $38.79 million, has announced the resumption of its CATT1 Phase 3 ...

VTV) was held by 19 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.

HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq ... reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on ...

Cheap, broad exposure to large-value stocks. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market ...